Vineti Stock

vineti.comHealthcareFounded: 2016Funding to Date: $115.3MM

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. This company was founded by Razmik Abnous, Amy DuRoss, Malek Faham, Heidi Hagen, Stephen Ting in 2016 and is headquartered in San Francisco, CA. Vineti's software solution Personalized Therapy Management (patent pending) automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Vineti, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Vineti investors also invested in these private companies

McKesson Ventures
Cardinal Health
Casdin Capital
Section 32

Team

Management Team

Amy DuRoss
Co-Founder & Chief Executive Officer
Joe DePinto
Chief Commercial Officer
Louise Rose Pacini
Chief Operations Officer
Phil Calvin
Chief Technology Officer
Brett Robertson
Chief Financial Officer
Heidi M. Hagen
Co-Founder
Subbu Viswanathan
Compliance Officer & SVP, Quality, Security & Compliance

Board Members

Nina Kjellson
Canaan Partners
Eli Casdin
Casdin Capital
Michael Pellini
Section 32
Michele Holcomb
Cardinal Health
John kontor
Optum
Neil Kurtz
Medidata
Emily Melton
Threshold Ventures

Other companies like Vineti in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$2.51B
Sector
Last Round Est. Valuation
$1.4B
Sector
Last Round Est. Valuation
$453MM
Sector
Last Round Est. Valuation
$1.65B
Sector
Last Round Est. Valuation
$355.29MM
Sector
Last Round Est. Valuation
$8.18B
Sector
Last Round Est. Valuation
$1.61B
Sector
Last Round Est. Valuation
$263MM

News

Vineti’s enterprise technology will enable critical patient-specific Chain of Custody management for Imvax, supporting Imvax’s goal of reaching more...
A coalition of drugmakers has agreed to work with Vineti, a San Francisco-based technology company, to usher in new standards that could ease some of the safety and logistic concerns surrounding advanced medicines like cell and gene therapies.
This $33 million extension to Vineti’s Series C in February 2020 will be used to further grow the company’s leading enterprise platform for advanced...